23ME-00610 is a clinical-stage therapeutic antibody, generated in-house, that is designed to restore the immune system’s ability to kill cancer cells by blocking the immune checkpoint CD200R1. CD200R1 is expressed by a broad array of immune cells capable of driving both innate and adaptive anti-tumor immune response. With high target binding affinity and favorable PK/PD, 23ME-00610 has potential to achieve clinically meaningful efficacy in a wide range of tumor types.
23ME-01473 is an antibody, generated in-house, that targets ULBP6, which can be expressed and secreted by tumor cells to suppress immune activity. 23ME-01473 induces immune activation through dual mechanisms that may restore anti-tumor immunity by NK and T cells. It is designed to overcome the lack of efficacy faced by some immune checkpoints due to loss of tumor antigen presentation and/or the inability to activate multiple arms of the immune system.
23andMe is pursuing discovery-stage programs in immunology and inflammation, where insights from our genetic database offer unique opportunities to advance meaningful therapeutic programs with the promise of identifying drugs to treat patients with serious unmet need. Our discovery efforts in this area have yielded a roadmap of genetic factors important for immune function across diverse diseases where the immune system plays a critical role. Our team is pursuing therapeutic antibody discovery programs to drug the most promising targets identified by these genetic findings.
The most advanced program between 23andMe and GSK is GSK6097608, which targets the inhibitory immune receptor CD96. CD96 has been shown to impact both T cell and NK cell function by competing with the co-stimulatory receptor CD226 for binding to shared ligands. GSK is currently advancing the program that gives 23andMe royalties if GSK6097608 is brought to market.
The discovery collaboration between 23andMe and GSK, which began in 2018, has generated more than 50 programs in immuno-oncology, cardiovascular/ metabolic, immunology and neurology. 23andMe is entitled to share in proceeds resulting from other jointly discovered programs according to the terms of the collaboration agreement.